Cell/Gene Tx channel feed – Endpoints News

Cell/Gene Tx channel feed

Updated: Cell therapy biotech Affini-T Therapeutics reduces staff

3 months ago

Cell therapy startup Aurion files for IPO, despite ongoing legal battle with investor Alcon

3 months ago

UK biotech launches with T cell therapy technology to treat solid tumors

3 months ago

Chinese startup begins first trial of in vivo CRISPR therapy for blood disease

3 months ago

FDA rejects Atara's cell therapy for rare transplant complication, stock craters

3 months ago

Vertex's bid to offer Casgevy fertility support is 'self-serving,' HHS says

3 months ago

Umoja’s $100M Series C will advance its bid for more convenient cell therapies

4 months ago

Post-Hoc: The embryo editing debate is back

4 months ago

Exclusive: Bucking gene editing downturn, Tune raises $175M to bring epigenetic editing to clinic

4 months ago

Shoreline cuts staff as its partnership with Gilead's Kite is now in flux

4 months ago

Exclusive: First-of-its-kind infant DNA edit leads to apparent cure in disease that set back field 25 years ago

4 months ago

Astellas stops developing autologous cell therapy using tech from Xyphos buyout

4 months ago

Vertex signs in vivo gene editing delivery pact for sickle cell and thalassemia as it looks beyond Casgevy

4 months ago

Pfizer ends work on Sangamo's hemophilia gene therapy, crushing biotech's hopes

4 months ago

WuXi AppTec will sell cell and gene therapy business to private equity firm

4 months ago

Mesoblast wins long-awaited approval for cell therapy

4 months ago

Sangamo strikes another brain-targeting AAV partnership, this time with Astellas

4 months ago

Updated: Flagship gene therapy startup Ring Therapeutics nearly halves workforce as CEO departs

4 months ago

Exclusive: Cell therapy startup Shinobi adds Borges as science chief, Katz as top medical officer

4 months ago

Bristol Myers drops cell therapy pacts with Immatics, Century as part of portfolio review

4 months ago

Roche terminates a Phase 3 Spark gene therapy in hemophilia A

4 months ago

Editas to cut 65% of workforce, officially stops work on ex vivo sickle cell therapy

5 months ago

Chroma, Nvelop merge to form nChroma Bio, raising $75M to enter the clinic

5 months ago

Arcellx and Gilead seek to unseat Legend and J&J with multiple myeloma cell therapy

5 months ago

First page Previous page 1 234 5 6 Next page Last page